VOR Profile
Vor Biopharma, Inc. is a clinical-stage biopharmaceutical company specializing in the development of engineered hematopoietic stem cell (eHSC) therapies designed to target and treat cancer. The company’s primary focus is on harnessing the potential of eHSCs to address hematological malignancies, including acute myeloid leukemia (AML) and other blood cancers.
The company’s lead product candidate, VOR33, is an innovative eHSC therapy currently in phase 1/2 clinical trials. VOR33 is engineered to lack CD33, a protein commonly expressed by AML cells. This targeted approach aims to enhance the efficacy of cancer treatments by specifically addressing cells that express CD33, thereby minimizing damage to healthy cells and improving therapeutic outcomes.
Vor Biopharma’s therapeutic strategy extends beyond VOR33 to include other advanced eHSC-based treatments. The company is developing a portfolio of targeted therapies, including CAR-T cells, bispecific antibodies, and antibody-drug conjugates. These therapies are designed to offer personalized treatment options for patients with various types of blood cancers, leveraging the specificity and potency of engineered stem cell technologies.
In addition to its internal development programs, Vor Biopharma has entered into a collaboration agreement with Akron BioProducts to advance the development and manufacture of cGMP (current Good Manufacturing Practice) nucleases. This partnership is expected to enhance the company’s capabilities in producing high-quality nucleases critical for its eHSC therapies. Founded in 2015 and headquartered in Cambridge, Massachusetts, Vor Biopharma continues to push the boundaries of cancer treatment through its cutting-edge stem cell technologies and strategic partnerships.
|
